文献速递心境障碍

基线抑郁严重程度对SSRIs疗效的影响:基于条目和患者水平的事后分析

Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
PubMed 文献 · Lancet Psychiatry · 2019-07-11

该研究汇总28项安慰剂对照SSRI试验的8262例成年重性抑郁患者数据,按基线HDRS-17总分≤18分为非严重组(654例)、≥27分为严重组(1377例),进行条目水平事后分析。结果显示,SSRIs对HDRS-6条目(含抑郁情绪)的改善在非严重与严重抑郁患者中无差异;而HDRS-17总分显示的严重度与疗效正相关,主要源于非HDRS-6条目在严重患者中基线更重、改善空间更大。

要点

  • SSRIs对HDRS-6条目(含抑郁情绪)的疗效在非严重与严重抑郁患者中无差异。
  • HDRS-17总分显示的严重度与疗效正相关,主要由非HDRS-6条目驱动。
  • 非严重患者因非HDRS-6条目基线轻、改善空间小,可致SSRIs无效的误判。

核心结论

  • 以包含基线轻症状的HDRS-17总分为疗效指标,可能误判SSRIs对非严重抑郁患者无效。
  • 就HDRS-6条目(含抑郁情绪)的改善而言,SSRIs对非严重抑郁与严重抑郁患者同样有效。

研究设计与样本

  • 研究为基于条目、患者水平的事后分析,汇总所有已完成的、急性期、安慰剂对照、药企赞助、基于HDRS的SSRIs试验。
  • 纳入西酞普兰、帕罗西汀或舍曲林治疗成年重性抑郁的试验,共28项安慰剂对照SSRI试验、8262例患者。
  • 患者接受西酞普兰(n=744)、帕罗西汀(n=2981)、舍曲林(n=1202)、氟西汀(活性对照,n=754)或安慰剂(n=2581)。
  • 非严重抑郁定义为基线HDRS-17总分≤18分(654例),严重抑郁定义为≥27分(1377例)。

主要发现

  • 非严重与严重抑郁患者在接受SSRI后,抑郁情绪及HDRS-6子量表中其他HDRS症状的下降无差异。
  • 排除罕见极端基线值后,以HDRS-17总分为疗效参数时,严重度与疗效呈正相关。
  • 该正相关主要因严重抑郁患者非HDRS-6条目的治疗反应更明显。
  • 非HDRS-6条目在严重病例中基线更重、更普遍,故非严重患者在这些领域改善空间更小。

关键数值与推荐

  • 非严重抑郁:基线HDRS-17总分≤18分;严重抑郁:基线HDRS-17总分≥27分。
  • 疗效评估采用HDRS-17总分、HDRS抑郁情绪条目、HDRS-6子量表及非HDRS-6的其余11个条目。

临床怎么用

  • 评估SSRIs疗效时应关注HDRS-6条目(含抑郁情绪)等核心症状,避免仅凭HDRS-17总分判断非严重患者无效。
  • 解读HDRS-17总分变化时需考虑非HDRS-6条目在非严重患者中基线轻、改善空间小的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reports claiming that antidepressants are effective only in patients with severe depression have affected treatment guidelines but these reports usually use a disputed measure of improvement, a decrease in the sum-score of the 17-item Hamilton Depression Rating Scale (HDRS-17), and are based on group-level rather than patient-level data. METHOD: In this item-based, patient-level, post-hoc analysis, we pooled data from all completed, acute-phase, placebo-controlled, industry-sponsored, HDRS-based trials of the SSRIs citalopram, paroxetine, or sertraline in adult major depression. Patient-level data were pooled and subjected to item-based post-hoc analyses to assess the effect of baseline severity of depression on the response to treatment as assessed with HDRS-17 sum score, the depressed mood item of the HDRS, a six-item HDRS subscale (HDRS-6), and the remaining 11 HDRS items not included in this subscale (non-HDRS-6). Patients were defined as having non-severe depression if they had a baseline HDRS-17 sum score of 18 points or less and as having severe depression if they had a score of 27 points or more. FINDINGS: Our study population consisted of 8262 patients from 28 placebo-controlled SSRI trials. Participants were treated with either citalopram (n=744), paroxetine (n=2981), sertraline (n=1202), fluoxetine (active-control group; n=754), or placebo (n=2581). 654 patients were defined as having non-severe depression and 1377 as having severe depression. Patients with non-severe and severe depression did not differ with respect to SSRI-induced decrease in depressed mood and other HDRS symptoms belonging to the HDRS-6 subscale. However, after exclusion of patients with rare extreme baseline values, a positive association was seen between severity and efficacy when using HDRS-17 sum score as the effect parameter. This result was largely due to a more pronounced response to treatment with respect to non-HDRS-6 items in patients with severe depression than in those with non-severe depression. This outcome could be explained by non-HDRS-6 items, more so than HDRS-6 items, being more severe and prevalent at baseline in severe than in non-severe cases; hence, less room was left for improvement in these areas in patients with non-severe depression. INTERPRETATION: The use of an outcome measure that includes symptoms that rate low at baseline in patients with non-severe depression might result in the interpretation that SSRIs are ineffective in these patients. With respect to alleviation of HDRS-6 items, SSRIs appear to be as effective in patients with non-severe depression as in those with severe depression. FUNDING: Swedish Medical Research Council, AFA Insurance, Swedish Brain Foundation, Sahlgrenska University Hospital (Avtal om Läkarutbildning och Forskning), Bertil Hållsten's Foundation, and Söderberg's Foundation.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hieronymus F, Lisinski A, Nilsson S, et al. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. Lancet Psychiatry. 2019. PMID: 31303567. doi:10.1016/S2215-0366(19)30216-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。